SUPERIOR COURT OF NEW JERSEY
APPELLATE DIVISION
A-5534-00T5
MARIA NOLAN, as Executrix
of the Estate of GUY NOLAN,
and MARIA NOLAN, individually,
Plaintiffs-Appellants,
v.
FIRST COLONY LIFE INSURANCE
COMPANY,
Defendant-Respondent,
and
PORTAMEDIC SERVICES, INC.,
DOMENIC SCHIRALDI, D.P.M.,
CLARA MAASS MEDICAL CENTER
and EDUARDO MONTEAGUDO, M.D.,
Defendants.
___________________________________
Argued October 9, 2001 - Decided November 13,
2001
Before Judges Petrella, Kestin and Alley.
On appeal from the Superior Court of New
Jersey, Law Division, Monmouth County, MON-L-
5709-98.
William Levinson argued the cause for
appellant (Eichen, Levinson, Cahn & Parra,
attorneys; Mr. Levinson, on the brief).
George J. Kenny of Connell Foley argued the
cause for respondent (Connell Foley and Blank
Rome Comisky & McCauley, attorneys; Mr. Kenny
and Jonathan M. Korn of Blank Rome Comisky &
McCauley, on the brief).
The opinion of the court was delivered by
PETRELLA, P.J.A.D.
This is an appeal by plaintiffs Maria Nolan, as Executrix of
the Estate of Guy Nolan, and Maria Nolan, individually, from
summary judgment in favor of First Colony Life Insurance Company
(First Colony) and dismissal of the second amended complaint
sounding in negligence, and originally malpractice.
In connection with his application for a $200,000 life
insurance policy from First Colony, Guy Nolan underwent a pre-
insurance screening and blood and urine test by Portamedic
Services, Inc. (Portamedic), an agency designated by First
Colony. Nolan was subsequently diagnosed with and died of liver
cancer two years later. PlaintiffSee footnote 11 claims that First Colony
violated its duty to the decedent by failing to disclose the
results of a blood test, which indicated elevated levels of two
liver enzymes. The issue on appeal is whether New Jersey case
law requires an insurance company to disclose the results of
blood test results above the "normal ranges" to the applicant for
insurance.See footnote 22 Plaintiff also contends that the denial of First
Colony's F.R.C.P. 12(b)(6) motion by the federal district court,
where the case was initially heard, has res judicata effect,
precluding First Colony from denying its duty to disclose the
blood test results.
Plaintiff filed a complaint against First Colony, a John
Doe, an unknown paramedic, and a James Doe, M.D., an unknown
physician, on November 13, 1998. The case was removed to the
federal district court for the District of New Jersey based on
diversity of citizenship jurisdiction. Defendants moved to
dismiss the complaint pursuant to F.R.C.P. 12(b)(6). In denying
the motion, the judge examined New Jersey case law and concluded
that the physician and the paramedic (factually it developed that
no physician or paramedic was involved) may have had a duty of
care to the decedent and that a patient-physician relationship
could arise based on the alleged factual contentions of the
complaint.
Plaintiff amended her complaint to include defendants
Domenic Schiraldi (Schiraldi) and Portamedic, thus vitiating
federal diversity jurisdiction. The case was remanded to the
Superior Court and plaintiff again amended the complaint to add
as defendants Clara Maass Medical Center and Eduardo Monteagudo,
M.D.See footnote 33
Both sides moved for summary judgment. The judge granted
summary judgment in favor of First Colony, Schiraldi and
Portamedic, and denied plaintiff's motion. In so ruling, the
judge found that First Colony was not vicariously liable for
medical malpractice because no medical doctor examined the
decedent; First Colony did not have a duty to disclose the test
results to the decedent; and the New Jersey Legislature never
imposed such a duty.
Plaintiff's motion for leave to appeal was granted as to the
dismissal of the complaint against First Colony. Leave to appeal
the dismissal of the complaints against Schiraldi and Portamedic
was denied. On January 23, 2001, our Supreme Court decided Reed
v. Bojarski,
166 N.J. 89 (2001), and we remanded for
reconsideration in light of Reed. The motion judge concluded
that Reed did not apply and reaffirmed summary judgment in favor
of First Colony. Plaintiff again sought and was granted leave to
appeal. We now affirm.
In October 1996, Guy Nolan, born on May 19, 1961, applied
for a $200,000 life insurance policy through First Colony. Part
of the application process required Nolan to undergo a physical
examination. The examination was administered by defendant
Portamedic, a company not affiliated with First Colony, on
November 11, 1996.See footnote 44 Portamedic's business involved performing
such examinations for insurance companies. Portamedic's employee
Schiraldi conducted the examination. Though Schiraldi graduated
from podiatric school, he was not a licensed medical doctor. The
examination involved having the decedent complete a
questionnaire,See footnote 55 taking measurements of height, weight, blood
pressure, heart rate and pulse, and taking blood and urine
samples.
The blood sample was sent to an independent laboratory and
the results, without medical analysis or conclusions, were sent
to First Colony. No medical doctor ever looked at the findings
of the lab prior to the issuance of the insurance policy. The
report indicated the decedent had low cholesterol and normal GGTP
levels, but that his SGOT, SGPT and triglyceride levels were
above normal. The SGOT and the SGPT levels were approximately
1.1 and 1.3 times the normal range, respectively.See footnote 66
Mary Dellinger had been employed by First Colony for eight
years, and was the underwriter who screened decedent's
application. She had no medical training, but reviewed the
laboratory report and compared the raw data to First Colony's
underwriting manual. She gave the elevated levels a rating of
zero. The file indicated that this would not result in an
adverse underwriting decision.See footnote 77 Dellinger approved the
application and First Colony issued the decedent a "Preferred"
policy around December 1, 1996. First Colony also had a "Best
Preferred," a "Standard" policy and rated policies. Nolan was
not issued a "Best Preferred" policy because Dellinger marked off
"medical reasons."See footnote 88
About two years later, in mid-1998, Guy Nolan was diagnosed
with metastatic adenocarcinoma of the liver. About October 8,
1998, Nolan requested and received a copy of the blood test
result conducted in association with his life insurance
application. Apparently, blood test results from a 1993
hospitalization for surgery were also requested and received.
Despite treatment of his condition, Nolan died on November 10,
1998. First Colony paid the full proceeds of the $200,000 policy
to the plaintiff, the policy's beneficiary.
SUPERIOR COURT OF NEW JERSEY
APPELLATE DIVISION
A-5534-00T5
MARIA NOLAN, as Executrix
of the Estate of GUY NOLAN,
and MARIA NOLAN, individually,
Plaintiffs-Appellants,
v.
FIRST COLONY LIFE INSURANCE
COMPANY,
Defendant-Respondent,
and
PORTAMEDIC SERVICES, INC.,
DOMENIC SCHIRALDI, D.P.M.,
CLARA MAASS MEDICAL CENTER
and EDUARDO MONTEAGUDO, M.D.,
Defendants.
________________________________________________
KESTIN, J.A.D. (concurring)
While I concur in the result my colleagues have reached, I
respectfully disagree with their view that an insurance company
has no duty to disclose abnormal blood test results to a policy
applicant. We seem to have different understandings of the
meaning of Reed v. Bojarski,
166 N.J. 89 (2001). I take the
Supreme Court's language quoted by my colleagues as a conclusion
flowing from a general principle, not a statement of the
principle itself. In the quoted passage, the Court undeniably
determined that, in the circumstances presented, no traditional
physician-patient relationship existed, but it also stated that
the existence of that relationship was of "no moment" because
"[t]he exact nature of the relationship is simply a factor to be
considered in determining what duty exists." Id. at 106. The
full meaning of that declaration can be understood only in the
light of the preceding paragraph:
As we have often said, "'whether a duty
exists is ultimately a question of fairness.
The inquiry involves a weighing of the
relationship of the parties, the nature of
the risk, and the public interest in the
proposed solution.'" Kelly v. Gwinnell,
96 N.J. 538, 544,
476 A.2d 1219 (1984) (quoting
Goldberg v. Housing Auth.,
38 N.J. 578, 583,
186 A.2d 291 (1962)). A duty is said to
arise out of the existence of a relationship
between the "parties such that social policy
justifies" its imposition. W. Page Keeton et
al., Prosser & Keeton on the Law of Torts, §
56, at 374 (5th ed. 1984).
[Ibid.]
Clearly, the Supreme Court continues to be of the view that tort
duties arise from the qualities of a relationship not the status
of the parties.
I disagree also that resolution of the question at issue
should be left to the Legislature. In the common law, the
development of tort jurisprudence has always been a judicial
function subject, of course, to legislative oversight. See
Thomas v. Romeis,
234 N.J. Super. 364, 370-72 (App. Div. 1989)
(stressing the courts' role in defining the limits of tort
liability and quoting from Kelly v. Gwinnell,
96 N.J. 538, 547
(1984) that "the duty involved is a common law duty, not one
arising from . . . statute and regulation"); Ritchie-Gamester v.
City of Berkley,
597 N.W.2d 517, 523 (Mich. 1999) (noting that in
the absence of legislative action, "the development of [the
common law of torts] is up to the courts"); Saunders v. Alford,
607 So.2d 1214, 1219 (Miss. 1992) (stating "[t]he common law is
not static" and rejecting the argument that abolition of a common
law tort can only be accomplished by the legislature); Russo v.
Sutton,
422 S.E.2d 750, 753 (S.C. 1992) (same). The Supreme
Court does not shrink from that role, and neither should we.
In order to reach a sensible result in this case, it is not
necessary to depart from the general rule that no tort duty
exists requiring every person who becomes aware of a danger to
another to take steps to warn the person at risk of the existence
of the threat. See Restatement (Second) of Torts, § 314 (1965
and pertinent appendices); 2 Dan B. Dobbs, The Law of Torts, §
314 (2001); see also Praet v. Borough of Sayreville,
218 N.J.
Super. 218, 223-24 (App. Div.), certif. denied,
108 N.J. 681
(1987). Here, we are not dealing with general duties, but rather
with those arising from a special relationship, see generally
Restatement (Second) of Torts, § 314A (1965 and pertinent
appendices); see also Safer v. Estate of Pack,
291 N.J. Super. 619, 625-26 (App. Div.), certif. denied,
146 N.J. 568 (1996); cf.
McIntosh v. Milano,
168 N.J. Super. 466, 483-84 (Law Div. 1979)
(citing Restatement (Second) of Torts, §§ 314, 314A, 315 (1965)),
which came to exist when plaintiff's decedent applied for life
insurance and defendant carrier undertook to process that
application. It may well be untenable, as a general matter, to
hold an insurance carrier in such circumstances to a duty beyond
simple disclosure of a discovered potential threat to life or
health, but requiring only that step hardly seems onerous. The
duty of disclosure could be fully discharged by the simple
expedient of sending all blood test results to all policy
applicants with a form letter suggesting that they should consult
their physicians regarding any readings outside of normal ranges.
I concur rather than dissent, however, because of
plaintiff's failure to make an adequate prima facie showing on
summary judgment befitting the nature of this case. Plaintiff's
claim, at bottom, is one for increased risk of harm, see, e.g.,
Scafidi v. Seiler,
119 N.J. 93, 101-09 (1990); Evers v.
Dollinger,
95 N.J. 399, 412-17 (1984), occasioned by defendant's
failure to disclose information which plaintiff contends raised
some question about her decedent's health. Although the concept
of increased risk of harm has developed primarily in the context
of medical malpractice claims, there is no logical reason why it
should not also be applied where other types of special
relationship exist. See, e.g., Snyder v. American Ass'n of Blood
Banks,
144 N.J. 269, 292-98 (1996); Restatement (Second) of
Torts, § 323 (1965 and pertinent appendices). Nevertheless, this
plaintiff has made no adequate showing that the information which
defendant failed to disseminate signified so patent a deviation
from good-health norms that it would likely have led her decedent
to consult a physician and that, in turn, the physician would
likely have been led to take diagnostic steps that would probably
have resulted in discovery of the condition that, if promptly
treated, would have forestalled or prevented the decedent's
death. I agree with the majority that Dr. Bell's certification
was properly excluded as net opinion. It was clearly inadequate
to satisfy the prima facie showing plaintiff was required to make
to defeat defendant's motion for summary judgment. The fact that
the policy issued to plaintiff's decedent was a level lower than
"best preferred" for "medical reasons," i.e., the slightly
"elevated LFT's" indicated, is no surrogate for plaintiff's
responsibility to make an adequate prima facie showing.
Footnote: 1 1 Although we recognize that Maria Nolan sues in both a representative and individual capacity, for simplicity we refer to plaintiffs in the singular hereinafter. Footnote: 2 2 Nolan's cholesterol level was reported as "low." As to the deviation and significance of such ranges see Merck Manual, p. 1374 (Home ed. 1997). Footnote: 3 3 These defendants were involved in decedent's medical treatment in 1994, but are not involved as respondents in this appeal. The complaint, as amended, alleged that decedent's prior medical records revealed "abnormal blood test results which were not disclosed to plaintiff's decedent." Footnote: 4 4 The blood chemistry report indicated that Nolan last had a meal at 9:11 a.m. on November 11, 1996, and the specimen was collected at 5:22 p.m. that date. The report also indicated: "Date Recd: 96/11/16 Date Rptd: 11/14/96" and "Serum: Normal." Footnote: 5 5 In his application Nolan answered in the affirmative question 1 on a medical history questionnaire which asked if he had "a regular care provider or treatment facility" and listed his doctor's name and address. He also checked "yes" in response to question 3f which asked if he had been treated for "hepatitis, internal bleeding, ulcer, colitis, diverticula, or disorder of the stomach, esophagus, liver, pancreas, spleen, intestines, colon, rectum, or anus." He specifically wrote what appears to be "Cholecystectomy" in 1993 at Clara Maass Memorial Center. See note 2 supra. He also noted under a family history section that his father died of kidney failure at age sixty-two. Footnote: 6 6 The underwriting guidelines identified the normal range for SGOT (AST) (glutamic oxaloacetic transaminase) as 0 U/L to 41 U/L (usually measured in Karmen units per liter). Nolan's reading was a 45. This was 1.098 times the maximum in the normal range, which can also be expressed as 9.8% above the normal range. The normal range for SGPT (ALT) was 0 to 45 and Nolan tested as 58. This was 1.289 times the maximum in the normal range, or it can be expressed as 28.9% above the normal range. GGT (GGTP) results showed 51 U/L with the normal range being 0 to 65 U/L. Alkaline Phosphatase was within the normal range. Footnote: 7 7 The underwriting guidelines stated that heightened liver enzyme levels could indicate alcohol abuse or special medical conditions, such as diabetes. Dellinger concluded from the questionnaire that decedent did not have either condition. Having reached that conclusion, the manual directed that if the GGTP levels were normal and the SGOT and/or SGPT levels were normal or less than two times above normal, there should be a risk rating of zero. Footnote: 8 8 A note in First Colony's file stated: "CASE APPROVED PREF NS COLLO 200k - NOT BEST DUE TO ELEVATED LFT'S."